Krystal Biotech (KRYS) Gross Margin (2023 - 2025)
Historic Gross Margin for Krystal Biotech (KRYS) over the last 3 years, with Q3 2025 value amounting to 95.64%.
- Krystal Biotech's Gross Margin rose 36100.0% to 95.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 94.26%, marking a year-over-year increase of 17100.0%. This contributed to the annual value of 93.09% for FY2024, which is 8000.0% down from last year.
- Latest data reveals that Krystal Biotech reported Gross Margin of 95.64% as of Q3 2025, which was up 36100.0% from 92.54% recorded in Q2 2025.
- Over the past 5 years, Krystal Biotech's Gross Margin peaked at 97.39% during Q3 2023, and registered a low of 91.45% during Q2 2024.
- Moreover, its 3-year median value for Gross Margin was 94.3% (2025), whereas its average is 93.97%.
- In the last 5 years, Krystal Biotech's Gross Margin tumbled by -53700bps in 2024 and then skyrocketed by 36100bps in 2025.
- Krystal Biotech's Gross Margin (Quarter) stood at 93.19% in 2023, then rose by 1bps to 94.57% in 2024, then increased by 1bps to 95.64% in 2025.
- Its Gross Margin stands at 95.64% for Q3 2025, versus 92.54% for Q2 2025 and 94.3% for Q1 2025.